Altimmune (ALT) Payables (2010 - 2026)
Altimmune (ALT) reported Payables of $1.5 million for Q1 2026, up 42.06% year-over-year from $1.1 million in Q1 2025, and down 43.69% on a QoQ basis from $2.7 million in Q4 2025.
Altimmune (ALT) has 17 years of Payables data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Payables rose 42.06% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 42.06% YoY) and the FY2025 annual result came in at $2.7 million, up 1187.68% from the prior year.
- Payables slipped to $1.5 million in Q1 2026 per ALT's latest filing, from $2.7 million in the prior quarter.
- Across five years, Payables topped out at $5.2 million in Q1 2023 and bottomed at $211000.0 in Q4 2024.
- The 5-year median for Payables is $2.7 million (2024), against an average of $2.6 million.
- The widest annual swing landed in 2022, when Payables jumped 23227.31%; it then plunged 89.81% in 2024.
- Tracing ALT's Payables over 5 years: stood at $4.8 million in 2022, then plunged by 56.91% to $2.1 million in 2023, then sank by 89.81% to $211000.0 in 2024, then surged by 1187.68% to $2.7 million in 2025, then sank by 43.69% to $1.5 million in 2026.
- Per Business Quant, the three latest ALT Payables figures stand at $1.5 million (Q1 2026), $2.7 million (Q4 2025), and $4.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Altimmune | 379.61 Mn | 379.61 Mn | - | 1.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.53 Mn |
| Dec 31, 2025 | 2.72 Mn |
| Sep 30, 2025 | 4.80 Mn |
| Jun 30, 2025 | 851,000.00 |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 1.13 Mn |
| Jun 30, 2024 | 2.69 Mn |
| Mar 31, 2024 | 3.76 Mn |
| Dec 31, 2023 | 2.07 Mn |
| Sep 30, 2023 | 3.05 Mn |
| Jun 30, 2023 | 4.04 Mn |
| Mar 31, 2023 | 5.24 Mn |
| Dec 31, 2022 | 4.80 Mn |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 2.87 Mn |
| Mar 31, 2022 | 2.21 Mn |
| Dec 31, 2021 | 2.03 Mn |
| Sep 30, 2021 | 6,083.00 |
| Jun 30, 2021 | 1.42 Mn |
| Mar 31, 2021 | 418,243.00 |
| Dec 31, 2020 | 612,293.00 |
| Sep 30, 2020 | 874,885.00 |
| Jun 30, 2020 | 827,217.00 |
| Mar 31, 2020 | 929,629.00 |
| Dec 31, 2019 | 18,232.00 |
| Sep 30, 2019 | 154,946.00 |
| Jun 30, 2019 | 433,821.00 |
| Mar 31, 2019 | 241,870.00 |
| Dec 31, 2018 | 444,456.00 |
| Sep 30, 2018 | 1.62 Mn |
| Jun 30, 2018 | 1.56 Mn |
| Mar 31, 2018 | 562,870.00 |
| Dec 31, 2017 | 178,777.00 |
| Sep 30, 2017 | 544,766.00 |
| Jun 30, 2017 | 1.18 Mn |
| Mar 31, 2017 | 839,465.00 |
| Dec 31, 2016 | 199.55 Mn |
| Sep 30, 2016 | 614,543.00 |
| Jun 30, 2016 | 711,106.00 |
| Mar 31, 2016 | 166,357.00 |
| Dec 31, 2015 | 521,122.00 |
| Sep 30, 2015 | 306,172.00 |
| Jun 30, 2015 | 208,456.00 |
| Mar 31, 2015 | 536,994.00 |
| Dec 31, 2014 | 391,396.00 |
| Jun 30, 2014 | 437,382.00 |
| Mar 31, 2014 | 471,803.00 |
| Dec 31, 2013 | 2.22 Mn |
| Sep 30, 2013 | 1.16 Mn |
| Jun 30, 2013 | 4.16 Mn |
| Mar 31, 2013 | 2.62 Mn |
| Dec 31, 2012 | 3.03 Mn |
| Sep 30, 2012 | 3.05 Mn |
| Jun 30, 2012 | 2.06 Mn |
| Mar 31, 2012 | 2.27 Mn |
| Dec 31, 2011 | 1.45 Mn |
| Sep 30, 2011 | 445,515.00 |
| Jun 30, 2011 | 2.48 Mn |
| Dec 31, 2010 | 3.13 Mn |